Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Novartis - Gevokizumab and IL-1 Beta (Details)

v3.20.4
Licensing and Other Arrangements - Novartis - Gevokizumab and IL-1 Beta (Details)
$ / shares in Units, $ in Thousands, € in Millions
 12 Months Ended
Aug. 24, 2017
USD ($)
item
agreement
$ / shares
shares
Aug. 24, 2017
EUR (€)
item
agreement
shares
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
shares
Dec. 31, 2017
USD ($)
Licensing and other arrangements          
Proceeds from issuance of common stock       $ 22,000  
Issuance of common stock, fair value       21,762  
Revenue from contracts with customers     $ 27,941 $ 17,276  
Common Stock          
Licensing and other arrangements          
Issuance of stock, net (in shares) | shares       1,000,000  
Issuance of common stock, fair value       $ 8  
Gevokizumab License Agreement | Common Stock          
Licensing and other arrangements          
Closing stock price (in dollars per share) | $ / shares $ 8.93        
Novartis Pharma AG | Gevokizumab License Agreement and IL-1 Target License Agreement          
Licensing and other arrangements          
Transaction price $ 40,200        
Cash payment received 25,700        
License agreement consideration received, repayment of debt 14,300        
Common stock premium $ 200        
Number of license agreements | agreement 2 2      
Number of arrangements | item 1 1      
Number of performance obligations | item 2 2      
Remaining performance obligations     0    
Revenue from contracts with customers     0 0 $ 40,200
Contract assets     0 0  
Contract liabilities     0 0  
Capitalized contract costs     $ 0 $ 0  
Novartis Pharma AG | Gevokizumab License Agreement          
Licensing and other arrangements          
License agreement consideration received $ 30,000        
Cash payment received 15,700        
License agreement consideration received, repayment of debt 14,300 € 12.0      
Proceeds from issuance of common stock 5,000        
Common stock premium 200        
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 438,000        
Agreement termination prior written notice period 6 months 6 months      
Novartis Pharma AG | Gevokizumab License Agreement | Common Stock          
Licensing and other arrangements          
Issuance of stock, net (in shares) | shares 539,131 539,131      
Purchase price (in dollars per share) | $ / shares $ 9.2742        
Issuance of common stock, fair value $ 4,800        
Novartis Pharma AG | IL-1 Target License Agreement          
Licensing and other arrangements          
Cash payment received $ 10,000